CLINICAL_TRIALS
trial_result
· 2015-02-19
Clinical Trial Update: AP23573 in Female Adult Patients With Recurrent or Persistent Endometrial Cancer (8669-019)(COMPLETED) [Phase 2]
Summary
A Phase 2 trial of AP23573 in female adults with recurrent or persistent endometrial cancer has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Merck Sharp & Dohme LLC | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED